William Conkling
Chief Executive Officer bei RAFAEL HOLDINGS, INC.
Vermögen: 941 136 $ am 31.03.2024
Profil
William Conkling is currently the President & Chief Executive Officer at Rafael Holdings, Inc. He is also an Independent Director at Cyclo Therapeutics, Inc. Additionally, he holds positions as a Director at Day Three Labs, Inc. and Cornerstone Pharmaceuticals, Inc. Previously, he served as the Vice President-Sales, Marketing & Market Access at Immunomedics, Inc. from 2018 to 2021.
Mr. Conkling completed his undergraduate studies at Fordham University and earned an MBA from The Leonard N Stern School of Business in 1998.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.03.2024 | 534 044 ( 2,24% ) | 918 556 $ | 31.03.2024 | |
CYCLO THERAPEUTICS INC
0,06% | 13.02.2024 | 16 245 ( 0,06% ) | 22 581 $ | 31.03.2024 |
Aktive Positionen von William Conkling
| Unternehmen | Position | Beginn |
|---|---|---|
| RAFAEL HOLDINGS, INC. | Chief Executive Officer | 01.02.2022 |
| CYCLO THERAPEUTICS, INC. | Director/Board Member | 02.05.2023 |
Day Three Labs, Inc.
 Day Three Labs, Inc. Information Technology ServicesTechnology Services Day Three Labs, Inc. is a cannabinoid CPG ingredient manufacturer that specializes in developing and commercializing novel cannabis product solutions. The company is based in Denver, CO, and has research operations in Israel. Day Three Labs taps into over 50 years of scientific research and plant study to reimagine existing cannabis offerings by delivering innovation and ingenuity to the cannabis industry. The company's portfolio includes proprietary pharmaceutical-grade infusion technologies with the objective of handing control of the cannabis experience to the everyday consumer. The company was founded by Rafi Cohen and Joshua David Rubin, and Joshua David Rubin has been the CEO since incorporation. | Director/Board Member | - |
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Director/Board Member | - |
Ehemalige bekannte Positionen von William Conkling
| Unternehmen | Position | Ende |
|---|---|---|
| IMMUNOMEDICS, INC. | Sales & Marketing | 01.03.2021 |
Ausbildung von William Conkling
| Fordham University | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CYCLO THERAPEUTICS, INC. | Health Technology |
| RAFAEL HOLDINGS, INC. | Finance |
| Private Unternehmen | 3 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
Day Three Labs, Inc.
Day Three Labs, Inc. Information Technology ServicesTechnology Services Day Three Labs, Inc. is a cannabinoid CPG ingredient manufacturer that specializes in developing and commercializing novel cannabis product solutions. The company is based in Denver, CO, and has research operations in Israel. Day Three Labs taps into over 50 years of scientific research and plant study to reimagine existing cannabis offerings by delivering innovation and ingenuity to the cannabis industry. The company's portfolio includes proprietary pharmaceutical-grade infusion technologies with the objective of handing control of the cannabis experience to the everyday consumer. The company was founded by Rafi Cohen and Joshua David Rubin, and Joshua David Rubin has been the CEO since incorporation. | Technology Services |
